Combining evidence from clinical trials in conditional or accelerated approval.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 4, p. 707, doi. 10.1002/pst.2302
- By:
- Publication type:
- Article
Works matching IS 15391604 AND DT 2023 AND VI 22 AND IP 4
Results: 12
1
2
Generalized phase I‐II designs to increase long term therapeutic success rate.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 4, p. 692, doi. 10.1002/pst.2301
- By:
- Publication type:
- Article
3
Quantification of follow‐up time in oncology clinical trials with a time‐to‐event endpoint: Asking the right questions.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 4, p. 671, doi. 10.1002/pst.2300
- By:
- Publication type:
- Article
4
The stratified win statistics (win ratio, win odds, and net benefit).
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 4, p. 748, doi. 10.1002/pst.2293
- By:
- Publication type:
- Article
5
Utilization of treatment effect on a surrogate endpoint for planning a study to evaluate treatment effect on a final endpoint.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 4, p. 633, doi. 10.1002/pst.2298
- By:
- Publication type:
- Article
6
Covariate handling approaches in combination with dynamic borrowing for hybrid control studies.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 4, p. 619, doi. 10.1002/pst.2297
- By:
- Publication type:
- Article
7
Bayesian optimal phase II designs with dual‐criterion decision making.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 4, p. 605, doi. 10.1002/pst.2296
- By:
- Publication type:
- Article
8
Propensity score‐based methods for causal inference and external data leveraging in regulatory settings: From basic ideas to implementation.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 4, p. 721, doi. 10.1002/pst.2294
- By:
- Publication type:
- Article
9
Statistical methods for handling missing data to align with treatment policy strategy.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 4, p. 650, doi. 10.1002/pst.2299
- By:
- Publication type:
- Article
10
Bayesian single‐to‐double arm transition design using both short‐term and long‐term endpoints.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 4, p. 588, doi. 10.1002/pst.2292
- By:
- Publication type:
- Article
11
Improving early phase oncology clinical trial design: The case for finding the optimal biological dose.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 4, p. 739, doi. 10.1002/pst.2291
- By:
- Publication type:
- Article
12
Issue Information.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 4, p. 585, doi. 10.1002/pst.2238
- Publication type:
- Article